All these observations indicate that dysfunction of the normal epigenetic status of the genome
can have dramatic consequences on normal cognitive function. These studies also suggest that
drugs that target the epigenome may represent viable therapies in treating various diseases affecting
cognition, including those targeted to cytosine methylation.